Evogene (EVGN) Reports Q2 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Evogene Reports Second Quarter 2016 Financial Results
August 11, 2016 7:05 AM EDTREHOVOT, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE: EVGN) (TASE: EVGN), a leading biotechnology company for the improvement of crop productivity and economics for the food, feed and fuel industries, announced today its financial results for the quarter and six months ended June 30, 2016.
Ofer Haviv, Evogene's President and CEO, stated: "Just three years ago Evogenes research and development programs were almost entirely focused on one market segment of seed traits, and within this segment primarily at... More
